Patent · US Active

Protein tyrosine kinase modulators and methods of use

US10059688B2 · kind B2 · utility

1Cited by

1References

19Claims

0Family size

Assignee

Betta Pharmaceuticals Co., Ltd · CN

Inventors

Shaojing Hu · Beijing, CN
Xiangyong LIU · Beijing, CN
Jinlong Bai · Beijing, CN
Wei Long · Beijing, CN

Key dates

Filing date	Sep 1, 2017
Grant date	Aug 28, 2018
Priority date	—
Expiry date	Sep 1, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.